Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex, fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility.
Erick Auma, Rencia Alberts, Brigitta Derendinger, Rouxjeane Venter, Elizabeth M Streicher, Samantha Pillay, Yonas T Ghebrekristos, Moses Mburu, Morten Ruhwald, Robin Warren, Adam Penn-Nicholson, Grant Theron, Margaretha de Vos
{"title":"Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex, fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility.","authors":"Erick Auma, Rencia Alberts, Brigitta Derendinger, Rouxjeane Venter, Elizabeth M Streicher, Samantha Pillay, Yonas T Ghebrekristos, Moses Mburu, Morten Ruhwald, Robin Warren, Adam Penn-Nicholson, Grant Theron, Margaretha de Vos","doi":"10.1093/cid/ciae614","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Drug susceptibility testing (DST) is essential for starting people on effective tuberculosis (TB) regimens. No published data exists for the high-throughput LiquidArray MTB-XDR (LA-XDR) test, which detects Mycobacterium tuberculosis complex (MTBC) and fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility (latter two have no rapid DSTs available).</p><p><strong>Methods: </strong>We enrolled people (n=720) with presumptive TB who provided two sputa for a Xpert MTB/RIF Ultra and a culture (MTBC reference standard). Phenotypic DST and Sanger sequencing were the composite reference standards. LA-XDR on the manual FluoroLyse and automated GenoXtract-fleXT (fleXT) DNA extraction methods were compared.</p><p><strong>Results: </strong>For MTBC, LA-XDR had similar sensitivities (85-87%) and specificities (99%) using each extraction method. Drug susceptibility sensitivities varied: 94% (95% CI: 86, 98) for fluoroquinolones, 64% (45, 80) for amikacin, and 88% (79, 93) for ethambutol (specificities 97-100%). 6/7 (86%) resistant linezolid isolates were detected. LA-XDR with fleXT had indeterminate proportions of 21/251 (8%), 2/251 (1%), 63/251 (25%), and 93/251 (37%) for fluoroquinolones, ethambutol, amikacin, and linezolid, respectively (amikacin and linezolid indeterminates higher with Fluorolyse-extracted DNA). In a hypothetical population of 100 smear-negative people with fluoroquinolone-resistant TB undergoing fleXT DNA extraction, 24/100 (24%) would be missed (one extraction error, two invalid results, 15 MTBC-negative, six fluoroquinolone-indeterminate, one false-susceptible).</p><p><strong>Conclusion: </strong>LA-XDR met the minimum WHO target product profile for a next-generation sputum-based moderate complexity DST with high fluoroquinolones and ethambutol resistance sensitivity, moderate amikacin resistance sensitivity, and promise for linezolid resistance, for which more data are needed. Improved LA-XDR MTBC detection would reduce missed resistance.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciae614","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Drug susceptibility testing (DST) is essential for starting people on effective tuberculosis (TB) regimens. No published data exists for the high-throughput LiquidArray MTB-XDR (LA-XDR) test, which detects Mycobacterium tuberculosis complex (MTBC) and fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility (latter two have no rapid DSTs available).
Methods: We enrolled people (n=720) with presumptive TB who provided two sputa for a Xpert MTB/RIF Ultra and a culture (MTBC reference standard). Phenotypic DST and Sanger sequencing were the composite reference standards. LA-XDR on the manual FluoroLyse and automated GenoXtract-fleXT (fleXT) DNA extraction methods were compared.
Results: For MTBC, LA-XDR had similar sensitivities (85-87%) and specificities (99%) using each extraction method. Drug susceptibility sensitivities varied: 94% (95% CI: 86, 98) for fluoroquinolones, 64% (45, 80) for amikacin, and 88% (79, 93) for ethambutol (specificities 97-100%). 6/7 (86%) resistant linezolid isolates were detected. LA-XDR with fleXT had indeterminate proportions of 21/251 (8%), 2/251 (1%), 63/251 (25%), and 93/251 (37%) for fluoroquinolones, ethambutol, amikacin, and linezolid, respectively (amikacin and linezolid indeterminates higher with Fluorolyse-extracted DNA). In a hypothetical population of 100 smear-negative people with fluoroquinolone-resistant TB undergoing fleXT DNA extraction, 24/100 (24%) would be missed (one extraction error, two invalid results, 15 MTBC-negative, six fluoroquinolone-indeterminate, one false-susceptible).
Conclusion: LA-XDR met the minimum WHO target product profile for a next-generation sputum-based moderate complexity DST with high fluoroquinolones and ethambutol resistance sensitivity, moderate amikacin resistance sensitivity, and promise for linezolid resistance, for which more data are needed. Improved LA-XDR MTBC detection would reduce missed resistance.
期刊介绍:
Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.